Biogen Inc. (BIIB)
After hours:
| Previous Close | 291.92 |
| Open | 292.36 |
| Bid | 279.00 x 800 |
| Ask | 290.66 x 2200 |
| Day's Range | 289.94 - 295.89 |
| 52 Week Range | 187.16 - 311.88 |
| Volume | |
| Avg. Volume | 1,228,142 |
| Market Cap | 42.611B |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | 15.04 |
| EPS (TTM) | 19.29 |
| Earnings Date | Feb 01, 2023 - Feb 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 295.44 |
- Zacks
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
- Reuters
UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen
Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The application to the EMA was based on results from a late-stage study that showed the drug slowed down the rate of cognitive decline in patients with early Alzheimer's by 27%, compared with a placebo. Eisai has also filed for approval of the drug in Japan.
- GlobeNewswire
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of
